B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? - Wikidata - awgldk - TriplyDB

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

http://www.wikidata.org/entity/Q26828763

about

Stem cell transplantation for primary immunodeficiency diseases: the North American experience Advances in basic and clinical immunology in 2013 Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for ZAP70 Deficiency.Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency The importance of bone marrow involvement in GVHD.Chemotherapy-free conditioning: one step closer.Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.Transplantation outcomes for severe combined immunodeficiency, 2000-2009.Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency.Long-lasting production of new T and B cells and T-cell repertoire diversity in patients with primary immunodeficiency who had undergone stem cell transplantation: a single-centre experience.History and current status of newborn screening for severe combined immunodeficiency.Radiation-sensitive severe combined immunodeficiency: The arguments for and against conditioning before hematopoietic cell transplantation--what to do?Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage.Primary Immune Deficiency Treatment Consortium (PIDTC) report.Survey on retransplantation criteria for patients with severe combined immunodeficiency.Advances in hematopoietic stem cell transplantation for primary immunodeficiency.Primary immunodeficiencies: a decade of shifting paradigms, the current status and the emergence of cutting-edge therapies and diagnostics.Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Conso Primary Immune Deficiency Treatment Consortium (PIDTC) update.(211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy.Longitudinal Evaluation of Immune Reconstitution and B-cell Function After Hematopoietic Cell Transplantation for Primary Immunodeficiency.B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.Unconditioned unrelated donor bone marrow transplantation for IL7Rα- and Artemis-deficient SCID.Long term outcomes of severe combined immunodeficiency: therapy implications.Efficacy of lentiviral mediated gene therapy in an Omenn syndrome Rag2 mouse model is not hindered by inflammation and immune dysregulation.Successful Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in a Severe Combined Immune Deficiency Patient: a First Report.A Practical Approach to Newborn Screening for Severe Combined Immunodeficiency Using the T Cell Receptor Excision Circle Assay.Hematopoietic cell transplantation in primary immunodeficiency - conventional and emerging indications.Cytoreductive conditioning for severe combined immunodeficiency--help or hindrance?Insufficient immune reconstitution after allogeneic cord blood transplantation without chemotherapy conditioning in patients with SCID caused by CD3δ deficiency.B cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation.Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency.

P2860

Q26827162-1A4D22BB-1E11-4030-BEEA-F62E633D4D09 Q27027001-2A3A0650-E38B-4252-86C6-60DD62063790 Q33434039-4F7A19EC-A07D-46AD-B159-0B3D64F872EC Q33722772-34B07B32-B6AB-46C8-AD11-E55C32B301F4 Q34019565-D5E50F3B-64EB-47B4-B76C-C4109F853216 Q34019569-310D9216-BD7B-4ABE-B214-DF6147EBA029 Q34268121-FD8EAA24-D20C-4639-B9B1-F5ACE78B74E3 Q34279715-A19DE51E-9162-496D-AD32-9FBC6639DFDB Q34294647-D24F298C-137D-44CB-AED8-D06E40E15346 Q34729193-E7AD3963-B869-41BC-B9D1-249C0832712E Q35613205-185D72F8-70FB-4514-8DDA-6CBD104C42AE Q36269199-629E428E-CE1C-4278-96BF-537A2A24CFC4 Q37358921-0F37926F-E77E-4BA4-AF62-CC5319A89493 Q37397003-4128E4EC-836B-4D1F-814B-A47A0EA4FE13 Q37649782-DA5B24EB-92D9-4F45-AB64-BDD8DFCDF0D1 Q37649786-4113E60A-E6A7-42C3-ACB6-47FE5000015A Q38152824-4778D947-0A44-4020-B5C9-E046AE2D776D Q38289442-CAD3DFB3-4D38-41B7-AF2E-5EBCE453198E Q38772827-AD155720-B2F9-4A21-BA6B-5E6F9221579E Q38855061-595964AF-AFBB-4635-91A3-CE86E0FA94BB Q41005562-B0E0E6DC-30D8-4E94-87BB-C618DC34C0FD Q41070585-0D5A8C29-5A17-49EF-910F-FB7DCEB11F8F Q41404616-60E58B11-1AB7-43C0-BC49-D17311D05A30 Q44575275-1AD9B742-1EC2-416C-962E-D63C3A8061C3 Q45872036-42A222AD-36E8-41D7-A189-F8FC437719E0 Q45875844-453FE351-AA99-4A46-8E3F-C52382041E26 Q46809480-69A508D9-BCB5-4FC4-A07C-D945FD83E6E7 Q47131379-1C92EBCE-61D3-42E7-97FF-F3D6682068FF Q47210347-8966DEC9-3CC2-403D-90B8-BEDF1B739B6B Q48027176-31B15DCF-1084-4D01-9AAC-4CA4F9679621 Q53141611-DDE396CB-CA7D-4E07-9D6A-972F2C511506 Q53819932-E5D47082-DF2F-4750-9F49-22A2EC878AA5 Q55334301-0DFB96F3-B7E3-4412-A0A0-C4CDA01A6678

P2860

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

http://www.wikidata.org/entity/Q26828763

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

@ast

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

@en

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

@nl

type

label

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

@ast

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

@en

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

@nl

prefLabel

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

@ast

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

@en

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

@nl

P1433

Q26828763-EE8D48DD-B1FB-4D12-A807-CAFF90E437CC

P1476

Q26828763-537C5D1B-DD79-4A33-9F70-0CAE12520CD2

P2093

Q26828763-23428E61-EC78-4177-8687-F44404916959

Q26828763-A5ECB6C7-4E18-41A5-8D22-4C6E6AF5609D

Q26828763-E0BE3892-BC33-4CFD-97B0-6C678B1EE52D

P2860

Q26828763-0911F67A-0F0F-435F-8075-9258F0E75A80

Q26828763-09F84057-D818-4805-B2E0-BE104DB6FF5F

Q26828763-0F63DCD3-87F3-47E6-82DE-FED9017B2991

Q26828763-1724C18B-9E10-4569-A8FB-363F68D8BAAA

Q26828763-3CB1C9A5-304F-47D6-8E13-DAD4B15CE9F4

Q26828763-4D94593B-AA89-41EA-9631-C920AE34B653

Q26828763-53F516C5-001C-4398-964B-05F5ECD3E486

Q26828763-56A56621-4508-4832-8A44-7A28901B7F3C

Q26828763-56AB849C-AD1C-4D4C-AB98-0A5A40DC7B06

Q26828763-580CDF77-93CE-4787-B9EF-AE0E97365D2A

P304

Q26828763-4CB6465E-CD8F-4A34-A37A-9C24D55655BB

P31

Q26828763-210345F8-31A5-418E-8088-11502E77AB32

P3181

Q26828763-22E42D39-1380-474A-9CDD-216FB866C058

P356

Q26828763-CD5A76E8-4012-4704-BA01-BDD36294A7BE

P407

Q26828763-988E5045-8698-496A-9719-EFBB11762FBA

P433

Q26828763-38ABAC1A-C738-4C64-98BA-8E2826CF59F1

P478

Q26828763-68FD2EFC-3CD2-4449-B0E2-C9334A7FCB8C

P577

Q26828763-49ACB5DD-F5BD-424A-B89F-323BD80F1990

P698

Q26828763-CA86ED65-69FE-43BE-9328-4295766FEA08

P932

Q26828763-D959AC31-3124-49FF-95B8-E2119492AE74

P3181

P356

J.JACI.2013.01.047

P1433

The Journal of Allergy and Clinical Immunology

P1476

B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?

@en

P2093

Elie Haddad

http://www.w3.org/2001/XMLSchema#string

Rebecca H. Buckley

http://www.w3.org/2001/XMLSchema#string

Sandrine Leroy

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis in clinical trials

B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review

Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.

Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning

The long quest for neonatal screening for severe combined immunodeficiency.

IL-21 is the primary common γ chain-binding cytokine required for human B-cell differentiation in vivo.

Post-transplantation B cell function in different molecular types of SCID

Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes.

Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras.

Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis.

P304

994-1000

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2822640

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.JACI.2013.01.047

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23465660

http://www.w3.org/2001/XMLSchema#string

P932

3615028

http://www.w3.org/2001/XMLSchema#string